## STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Ite m No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragra ph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1/Line33- Page2Line40	Abstract/Paragraph2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page1/Line25- Page2/Line55	Abstract/Paragraph1-4
Introduction				
Backgr ound/	2	Explain the scientific background and rationale for the investigation being reported	Page2/Line61- Page3/Line98	Introduction/Paragraph1-2
Objectives	3	State specific objectives, including any prespecified hypotheses	Page3/Line 99-102	Introduction/Paragraph3
Methods			-	1
Study design	4	Present key elements of study design early in the paper	Page4/Line131- Page5/Line169	Methods/Paragraph3-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page4/Line 116-118	Methods/Paragraph2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants.  Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Page/Line 116-130	Methods/Paragraph2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	N/A	This study is a Cross-sectional study.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page5/Line137-149, Page5/Line153- Page6/Line169, Page4/Line122-130,	Methods/Paragraph2,4,7
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group	Page5/Line137-149, Page5/Line153- Page6/Line169	Methods/Paragraph4,7
Bias	9	Describe any efforts to address potential sources of bias	Page5/Line 145-149 and Page5/Line160- Page6/Line169	Methods/Paragraph6,8
Study size	10	Explain how the study size was arrived at	Page4/Line 106-112	Methods/Paragraph1

Statisti	12	(a) Describe all statistical methods, including those used to control for confounding	Page6/Line 173-179	Methods/Paragraph9	
cal metho		(b) Describe any methods used to examine subgroups and interactions	Page6/Line 176-179	Methods/Paragraph9	
ds		(c) Explain how missing data were addressed	N/A	There is no missing data in this study.	
		(d) <b>Cohort study</b> —If applicable, explain how loss to follow-up was addressed <b>Case-control study</b> —If applicable, explain how matching of cases and controls was addressed <b>Cross-sectional study</b> —If applicable, describe analytical methods taking account of sampling strategy	Page5/Line164- Page6/Line168	Methods/Paragraph7	
		(e) Describe any sensitivity analyses	N/A	There is no sensitivity analyses in this study.	
Results			•	•	
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page6/Line 183-190	Results/Paragraph1	
		(b) Give reasons for non-participation at each stage	N/A	No participants dropped out of the study.	
		(c) Consider use of a flow diagram	N/A	There is no need for a flow diagram in a cross-sectional study.	
Descriptive data	14 *	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page6/Line 183-190 and table 2	Results/Paragraph1	
		(b) Indicate number of participants with missing data for each variable of interest	N/A	There is no missing data in this study.	
		(c) <b>Cohort study</b> —Summarise follow-up time (eg, average and total amount)	N/A	This is not a cohort study.	
Outcome data	Outcome data	15 *	Cohort study—Report numbers of outcome events or summary measures over time	N/A	This is not a cohort study.
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	This is not a Case-control study.	
		Cross-sectional study—Report numbers of outcome events or summary measures	Page7/Line204- Page8/Line242	Results/Paragraph3-5	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page6/Line 194-200	Results/Paragraph2	
		(b) Report category boundaries when continuous variables were categorized	N/A	There is no relative data in our study.	

		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	There is no relative data in our study.	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page6/Line 194-200	Results/Paragraph2	
Discussion					
Key results	18	Summarise key results with reference to study objectives	Page8/Line 246-248	Discussion/Paragraph1	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page9/Line 300-302	Discussion/Paragraph5	

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page8/Line249- Page9/Line283	Discussion/Paragraph2-3
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page9/Line 284-299	Discussion/Paragraph4-5
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page10/Line 316	Acknowledgments/Para graph1

<sup>\*</sup>Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: <a href="https://dx.doi.org/10.21037/atm-22-2171">https://dx.doi.org/10.21037/atm-22-2171</a>

<sup>\*</sup>As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.